Statistik Asas
| LEI | 549300OC7SSPSNNGHE64 |
| CIK | 1746466 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Equillium, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 14, 2025 |
Exhibit 4.5 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 12, 2025, is entered into by and among Equillium, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used herein |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38692 EQUILLIUM, |
|
| August 11, 2025 |
EX-10.1 Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 10, 2025, by and among Equillium, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executi |
|
| August 11, 2025 |
Form of Pre-Funded Warrant to Purchase Common Stock EX-4.2 Exhibit 4.2 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUCH SE |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2025 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 11, 2025 |
Form of Registration Rights Agreement EX-4.1 Exhibit 4.1 Final Form REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August [], 2025, is entered into by and among Equillium, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized |
|
| August 4, 2025 |
Risks Related to Our Financial Position and Need for Additional Capital Exhibit 99.2 Risks Related to Our Financial Position and Need for Additional Capital Our need for additional capital raises substantial doubt about our ability to continue as a going concern. We will require substantial additional funding, in the immediate term, to continue operations and to resume and complete the planned or future development and any commercialization of EQ504, EQ302 and any fut |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2025 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 4, 2025 |
Exhibit 99.1 4 AUGUST 2025 Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced a strategic expansion to integrate a cryptocurrency treasury reserve strategy as part of its broader financial and growth objectives. “ |
|
| August 4, 2025 |
EX-10.1 Exhibit 10.1 OPEN MARKET SALE AGREEMENTSM October 5, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Equillium, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common |
|
| June 13, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 22, 2025 |
Equillium, Inc. 2018 Equity Incentive Plan, as amended. Exhibit 10.1 EQUILLIUM, INC. 2018 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: October 1, 2018 APPROVED BY THE STOCKHOLDERS: October 1, 2018 IPO DATE: October 11, 2018 AMENDED BY THE BOARD OF DIRECTORS: MARCH 26, 2025 APPROVED BY THE STOCKHOLDERS: MAY 21, 2025 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the E |
|
| May 22, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38692 EQUILLIUM |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 24, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 24, 2025 |
Equillium Announces Feedback from the U.S. Food and Drug Administration Exhibit 99.1 Equillium Announces Feedback from the U.S. Food and Drug Administration LA JOLLA, California, April 24, 2025 – Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that the company has received feedback from its Type D me |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 10, 2025 |
DEF 14A 1 eq-def14a-2025.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as p |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 27, 2025 |
Exhibit 99.1 Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights Announced topline data from the Phase 3 EQUATOR study in first-line acute graft-versus-host disease Breakthrough Therapy designation and meeting request to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025 LA JOLLA, California, |
|
| March 27, 2025 |
Exhibit 10.24 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CONFIDENTIAL Final Execution Version STOCK PURCHASE AGREEMENT by and among Equillium, Inc., Ariagen, Inc., The Stockholders of Ariagen, Inc. Listed |
|
| March 27, 2025 |
Subsidiaries of Equillium, Inc. Exhibit 21.1 SUBSIDIARIES OF EQUILLIUM, INC. Name of Subsidiary Jurisdiction of Incorporation Equillium AUS Pty Ltd. Australia Bioniz Therapeutics, Inc. Delaware Ariagen, Inc. Delaware |
|
| March 27, 2025 |
Exhibit 19.1 EQUILLIUM, INC. INSIDER TRADING POLICY Persons Covered This Insider Trading Policy of Equillium, Inc. (the “Company”) applies to all directors, officers, other employees and consultants of the Company and its subsidiaries. It also applies to their family members who reside with them, anyone else who lives in their households and any family members who do not live in their households b |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38692 EQUILLIUM, INC. |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 13, 2024 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 10, 2024 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 14, 2024 |
EQ / Equillium, Inc. / Decheng Capital Management IV (Cayman), LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2427620d26sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Equillium, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 29446K106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check |
|
| November 13, 2024 |
Exhibit 99.1 Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates Equillium retains rights to itolizumab following substantial funding from Ono partnership Evaluating accelerating Phase 3 EQUATOR study in aGVHD to completion in Q1 2025 Phase 2 ulcerative colitis study recently completed; topline data expected Q1 2025 LA JOLLA, California, November 13, |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38692 EQUIL |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 30, 2024 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 31, 2024 |
EX-99.1 Exhibit 99.1 Itolizumab Update October 31, 2024 Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements about Equillium, Inc. (the “Company”). In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “ongoing,” or the negative of |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 30, 2024 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38692 EQUILLIUM, |
|
| August 8, 2024 |
Exhibit 99.1 Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights $33.3 million cash balance at the end of Q2 2024, representing a $1.0 million increase from the end of Q1 2024 Triggered Ono option exercise period to acquire Equillium’s rights to itolizumab, decision expected before the end of October 2024 Announced positive interim analysis |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 19, 2024 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| July 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2024 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 4, 2024 |
EQ101: Phase 2 Topline Data in Alopecia Areata June 2024 Exhibit 99.1 This presentation contains forward-looking statements about Equillium, Inc. (the “Company”). In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable te |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 9, 2024 |
Exhibit 10.1 Equillium, Inc. 2024 Inducement Plan Adopted by the Board of Directors: March 6, 2024 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635-1, and |
|
| May 9, 2024 |
Exhibit 99.1 Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights $32.3 million cash balance at the end of Q1 2024 expected to provide cash runway into 2H 2025 Announced positive topline data from Phase 1b EQUALISE study of itolizumab in lupus nephritis patients, representing the first of two data sets that will trigger Ono Pharmaceutical’s option exercise |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38692 EQUILLIUM |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 11, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 1, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38692 EQUILLIUM, INC. |
|
| March 25, 2024 |
Subsidiaries of Equillium, Inc. Exhibit 21.1 SUBSIDIARIES OF EQUILLIUM, INC. Name of Subsidiary Jurisdiction of Incorporation Equillium AUS Pty Ltd. Australia Bioniz Therapeutics, Inc. Delaware |
|
| March 25, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Equillium, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 25, 2024 |
Exhibit 99.1 Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights $40.9 million cash balance at the end of 2023 expected to provide cash runway into 2H 2025 Completed enrollment of Phase 2 clinical study of EQ101 in alopecia areata: topline data expected in Q2 2024 Presented positive data from Phase 1b EQUALISE study of itolizumab in lupus |
|
| March 25, 2024 |
Incentive Compensation Recoupment Policy. Exhibit 97.1 EQUILLIUM, INC. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Equillium, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) p |
|
| March 25, 2024 |
As filed with the Securities and Exchange Commission on March 25, 2024 As filed with the Securities and Exchange Commission on March 25, 2024 Registration No. |
|
| March 8, 2024 |
EQUILLIUM, INC. 2024 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: March 6, 2024 EX-99.1 Exhibit 99.1 EQUILLIUM, INC. 2024 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: March 6, 2024 1. GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635 |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 23, 2024 |
Up to $21,950,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-269153 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated October 5, 2023 and Prospectus dated January 18, 2023) Up to $21,950,000 Common Stock This Prospectus Supplement amends and supplements the information in the prospectus supplement, dated October 5, 2023 (the “ATM Prospectus Supplement”), relating to the offer and sale of shares of ou |
|
| February 23, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2024 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2024 Equillium, Inc. |
|
| January 19, 2024 |
EX-99.2 3 exhibit992011924.htm EX-99.2 Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock of Equillium, Inc. and further agree to the filing of this agreement as an Exhibit th |
|
| January 19, 2024 |
EQ / Equillium, Inc. / TAKEDA PHARMACEUTICAL CO LTD - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EQUILLIUM, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 29446K106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| January 19, 2024 |
EX-99.1 2 exhibit991011924.htm EX-99.1 Exhibit 99.1 Identification of the subsidiary which acquired the security being reported on by the parent holding company. Takeda Pharmaceutical Company Limited’s (“Takeda”) beneficial ownership of the issuer’s common stock (“Common Stock”) consists of 1,842,977 shares of Common Stock held by Takeda Ventures, Inc. (“TVI”). TVI is wholly owned directly by Take |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 8, 2023 |
Exhibit 99.2 Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates $46.3 million in cash at the end of Q3 2023 expected to provide operating runway into 2025 $1.9 million of cash used in operating activities in Q3 2023 LA JOLLA, California, November 8, 2023 – Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understa |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 6, 2023 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 8, 2023 |
Exhibit 99.1 Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology Itolizumab continues to show clinically meaningful response in highly proteinuric subjects At Week 28, 73% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR) Itolizumab demonstrated a favorable safety and tolerability profile LA JOL |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38692 EQUIL |
|
| October 16, 2023 |
Exhibit 99.1 Analyst & Investor Day With Dr. Arash Mostaghimi October 16, 2023 Forward-Looking Statements This presentation contains forward-looking statements about Equillium, Inc. (the Actual results or events could differ materially from the plans, intentions and “Company”). In some cases, you can identify forward-looking statements by expectations disclosed or implied in the forward-looking st |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| October 5, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-269153 PROSPECTUS SUPPLEMENT (To Prospectus dated January 18, 2023) Up to $6,340,000 Common Stock We have entered into an Open Market Sale AgreementSM, or sales agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordanc |
|
| October 5, 2023 |
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM October 5, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Equillium, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, p |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 9, 2023 |
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY […***…], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38692 EQUILLIUM, |
|
| August 9, 2023 |
Exhibit 99.1 Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates $48.4 million in cash at the end of Q2 2023 expected to provide operating runway into 2025 Fully prepaid and retired debt facility Authorized $7.5 million stock repurchase program LA JOLLA, California, August 9, 2023 – Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company |
|
| August 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 9, 2023 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 9, 2023 |
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY […***…], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 11, 2023 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 11, 2023 |
Exhibit 99.1 Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates $62.0 million cash balance at the end of Q1 2023 expected to provide operating runway into 2025 Presented Phase 1b EQUATE data in aGVHD highlighting rapid and durable rates of overall clinical response, clinical response associated with improved progression-free survival through one year, and steroid |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38692 EQUILLIUM |
|
| April 13, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 11, 2023 |
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 5, 2023 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 31, 2023 |
PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38692 EQUILLIUM, INC. |
|
| March 23, 2023 |
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| March 23, 2023 |
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| March 23, 2023 |
EX-99.1 Exhibit 99.1 Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates $71.0 million cash balance at the end of 2022 expected to provide cash runway into 2025 Acquired Bioniz Therapeutics, including two first-in-class clinical-stage assets, EQ101 and EQ102, and proprietary product discovery platform Initiated Phase 2 clinica |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 23, 2023 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 23, 2023 |
Subsidiaries of Equillium, Inc. Exhibit 21.1 SUBSIDIARIES OF EQUILLIUM, INC. Name of Subsidiary Jurisdiction of Incorporation Equillium AUS Pty Ltd. Australia Bioniz Therapeutics, Inc. Delaware Triumph Acquisition Sub, Inc. Delaware Equillium Acquisition Sub, Inc. Delaware Triumph Merger Sub, Inc. Delaware |
|
| March 3, 2023 |
EQ / Equillium Inc / VICTORY CAPITAL MANAGEMENT INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. 5)* Equillium, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29446K106 (CUSIP Number) February 28, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| February 23, 2023 |
Equillium, Inc. 2223 Avenida de la Playa Suite 105 La Jolla, California 92037 RW Equillium, Inc. 2223 Avenida de la Playa Suite 105 La Jolla, California 92037 February 23, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Equillium, Inc. Request for Withdrawal of Registration Statement on Form S-4 File No. 333-268024 Dear Mr. Buchmiller: Pursuant to Rule 477 of the Securi |
|
| January 31, 2023 |
EQ / Embarq Corp / VICTORY CAPITAL MANAGEMENT INC Passive Investment SC 13G/A 1 equillium13ga4123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. 4)* Equillium, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29446K106 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| January 13, 2023 |
Equillium, Inc. 2223 Avenida de la Playa Suite 105 La Jolla, CA 92037 Equillium, Inc. 2223 Avenida de la Playa Suite 105 La Jolla, CA 92037 January 13, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell Re: Equillium, Inc. Registration Statement on Form S-3 Filed: January 6, 2023 File No. 333-269153 Ladies and Gentlemen: Pursuant to Rule 461 under the Securitie |
|
| January 6, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Equillium, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly R |
|
| January 6, 2023 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.9 EQUILLIUM, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF EQUILLIUM, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between EQUILLIUM, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the laws of [?] and |
|
| January 6, 2023 |
As filed with the Securities and Exchange Commission on January 6, 2023 As filed with the Securities and Exchange Commission on January 6, 2023 Registration No. |
|
| January 6, 2023 |
Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.6 EQUILLIUM, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 7 Section 2.0 |
|
| January 6, 2023 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.10 EQUILLIUM, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF EQUILLIUM, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between EQUILLIUM, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the laws o |
|
| January 6, 2023 |
EX-FILING FEES 4 d448098dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Equillium, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of |
|
| January 6, 2023 |
As filed with the Securities and Exchange Commission on January 6, 2023 S-3 1 d448314ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on January 6, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1554746 (State or other jurisdiction of inc |
|
| January 6, 2023 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.11 EQUILLIUM, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF EQUILLIUM, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between EQUILLIUM, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the laws o |
|
| December 23, 2022 |
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement Exhibit 99.1 Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement LA JOLLA, California, December 23, 2022 ? Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. today announced the mutual termination of their previously announced definitive merger agreement. ?Equillium first set out to acquire Metacrine in an all-stock transaction in early 2022, with the intent of adding cas |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 20, 2022 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 14, 2022 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 15, 2022 |
425 1 d429598d425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 14, 2022 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorpo |
|
| December 6, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 5, 2022 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 6, 2022 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 5, 2022 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 6, 2022 |
Filings under Rule 425 under the Securities Act of 1933 425 1 d406851d425.htm 425 Filings under Rule 425 under the Securities Act of 1933 and deemed filed under Rule 14a-12 of the Securities Exchange Act of 1934 Filing by: Equillium, Inc. Subject Company: Equillium, Inc. SEC File No.: 333-268024 C O R P O R A T E P A R T I C I P A N T S Bruce Steel, Chief Executive Officer, Equillium, Inc. C O N F E R E N C E C A L L P A R T I C I P A N T S Catherine N |
|
| December 6, 2022 |
Exhibit 99.1 Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab Equillium grants Ono an option to purchase rights to itolizumab Equillium to receive an upfront payment of approximately $26.0M (?3.5B); eligible to receive up to approximately $138.5M (?18.7B) in option exercise and milestone payments Ono to |
|
| December 6, 2022 |
Equillium & Ono Pharmaceutical Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab 6 December 2022 Exhibit 99. |
|
| November 14, 2022 |
Exhibit 99.1 Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates Announced positive interim results from the EQUALISE study of itolizumab in highly proteinuric lupus nephritis patients: by week 28, 83% achieved complete or partial response, and 67% achieved > 80% reduction in urine protein creatinine ratio Announced the pending acquisition of Metacrin |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38692 EQUIL |
|
| November 14, 2022 |
Filings under Rule 425 under the Securities Act of 1933 and deemed filed under Rule 14a-12 of the Securities Exchange Act of 1934 Filing by: Equillium, Inc. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 14, 2022 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File |
|
| November 10, 2022 |
MERGER PROPOSAL—YOUR VOTE IS VERY IMPORTANT 424B3 1 ny20005283x4424b3.htm 424B3 TABLE OF CONTENTS Filed pursuant to Rule 424(b)(3) Registration No. 333-268024 MERGER PROPOSAL—YOUR VOTE IS VERY IMPORTANT Dear stockholders of Equillium, Inc. and stockholders of Metacrine, Inc.: As previously announced, the board of directors of Equillium, Inc., or Equillium, and the board of directors of Metacrine, Inc., or Metacrine, have approved an acq |
|
| November 9, 2022 |
Exhibit 99.2 November 9, 2022 Board of Directors Metacrine, Inc. (in its capacity as such) 3985 Sorrento Valley Blvd, Suite C San Diego, CA 92121 Members of the Board of Directors: We hereby consent to the inclusion of our opinion letters, dated September 2, 2022 and October 19, 2022, to the Board of Directors of Metacrine, Inc. (“Metacrine”) as Annexes C-1 and C-2, respectively, to, and reference |
|
| November 9, 2022 |
Exhibit 99.5 |
|
| November 9, 2022 |
As filed with the Securities and Exchange Commission on November 9, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 9, 2022 Registration No. |
|
| November 9, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-4 (Form Type) Equillium, Inc. (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0001 per |
|
| November 9, 2022 |
Equillium, Inc. 2223 Avenida de la Playa, Suite 105 La Jolla, California 92037 CORRESP 1 filename1.htm Equillium, Inc. 2223 Avenida de la Playa, Suite 105 La Jolla, California 92037 November 9, 2022 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller Re: Equillium, Inc. Registration Statement on Form S-4 (File No. 333-268024) Dear Mr. Austin: This letter is sent on behalf of |
|
| November 9, 2022 |
Exhibit 99.4 |
|
| November 9, 2022 |
Exhibit 99.1 November 8, 2022 Board of Directors Equillium, Inc. 2223 Avenida de la Playa, Suite 105 La Jolla, CA 92037 Re: Amendment No. 1 to the Registration Statement on Form S-4 of Equillium, Inc. (File No. 333-268024), filed on November 8, 2022, relating to shares of Common Stock, par value $0.0001 per share (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our opinion |
|
| November 9, 2022 |
SUBSIDIARIES OF EQUILLIUM, INC. Exhibit 21.1 SUBSIDIARIES OF EQUILLIUM, INC. Name of Subsidiary Jurisdiction of Incorporation Equillium AUS Pty Ltd. Australia Bioniz Therapeutics, Inc. Delaware Triumph Acquisition Sub, Inc. Delaware Equillium Acquisition Sub, Inc. Delaware Triumph Merger Sub, Inc. Delaware |
|
| October 27, 2022 |
Exhibit 99.1 October 26, 2022 Board of Directors Equillium, Inc. 2223 Avenida de la Playa, Suite 105 La Jolla, CA 92037 Re: Initially Filed Registration Statement on Form S-4 of Equillium, Inc. (File No. 333- ), filed on October 26, 2022, relating to shares of Common Stock, par value $0.0001 per share (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our opinion letter, dat |
|
| October 27, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-4 (Form Type) Equillium, Inc. (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0001 per |
|
| October 27, 2022 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 27, 2022 Registration No. |
|
| October 27, 2022 |
Exhibit 99.4 |
|
| October 27, 2022 |
Exhibit 99.2 October 25, 2022 Board of Directors Metacrine, Inc. (in its capacity as such) 3985 Sorrento Valley Blvd, Suite C San Diego, CA 92121 Members of the Board of Directors: We hereby consent to the inclusion of our opinion letters, dated September 2, 2022 and October 19, 2022, to the Board of Directors of Metacrine, Inc. (“Metacrine”) as Annexes C-1 and C-2, respectively, to, and reference |
|
| October 27, 2022 |
SUBSIDIARIES OF EQUILLIUM, INC. Exhibit 21.1 SUBSIDIARIES OF EQUILLIUM, INC. Name of Subsidiary Jurisdiction of Incorporation Equillium AUS Pty Ltd. Australia Bioniz Therapeutics, Inc. Delaware Triumph Acquisition Sub, Inc. Delaware Equillium Acquisition Sub, Inc. Delaware Triumph Merger Sub, Inc. Delaware |
|
| September 28, 2022 |
425 1 d374196d425.htm 425 Filed by Equillium, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-38692 Subject Company: Metacrine, Inc. Commission File No.: 001-39512 Date: September 27, 2022 Event ID: 8770084 Event Title: Equillium Announces Interim Data from Type B Portion of EQUALISE Study in Patients with Lupus Nephritis Date: 09/27/2022 Executives: Bruce Steel |
|
| September 27, 2022 |
EQUALISE Interim Data Type B: Lupus Nephritis Patients 27 September 2022 Exhibit 99. |
|
| September 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 27, 2022 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File |
|
| September 27, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 27, 2022 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 26, 2022 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File |
|
| September 26, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 26, 2022 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File |
|
| September 26, 2022 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information is presented to illustrate the estimated effects of the proposed acquisition by Equillium, Inc. (?Equillium? or the ?Company?) of Metacrine, Inc. (?Metacrine?) pursuant to an Agreement and Plan of Merger (the ?Merger Agreement?) executed on September |
|
| September 26, 2022 |
Exhibit 99.3 On September 6, 2022, Equillium, Inc., or Equillium, Equillium Acquisition Sub, Inc., a Delaware corporation and wholly owned subsidiary of Equillium, or Acquisition Sub, Triumph Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Acquisition Sub, or Merger Sub, and Metacrine, Inc., a Delaware corporation, or Metacrine, entered into an Agreement and Plan of Merger, |
|
| September 26, 2022 |
Report of Independent Registered Public Accounting Firm Exhibit 99.1 Report of Independent Registered Public Accounting Firm To the Stockholders and the Board of Directors of Metacrine, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Metacrine, Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, convertible preferred stock |
|
| September 7, 2022 |
Filed by Equillium, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-38692 Subject Company: Metacrine, Inc. Commission File No.: 001-39512 Date: September 7, 2022 The following is a transcript of the audio recording of a conference call that took place on September 7, 2022 regarding the strategic transaction. The audio recording was made available on Equillium, I |
|
| September 6, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2022 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2022 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 6, 2022 |
Equillium Acquisition of Metacrine, Inc. September 7, 2022 Exhibit 99.2 This presentation contains forward-looking statements about Equillium, Inc. (the ?Company?). Statements contained in this presentation that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the us |
|
| September 6, 2022 |
Exhibit 99.1 Equillium to Acquire Metacrine in All-Stock Transaction Expected to add $33 million in cash at closing to Equillium?s balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642, an orally delivered Phase 2 ready FXR agonist for ulcerative colitis Preston Klassen, M.D., MHS, to be appointed to the Board of Directors LA JOLLA, California, Septem |
|
| September 6, 2022 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among EQUILLIUM, INC., METACRINE, INC., EQUILLIUM ACQUISITION SUB, INC. and TRIUMPH MERGER SUB, INC. Dated as of September 6, 2022 TABLE OF CONTENTS Page ARTICLE I THE MERGER; CLOSING; SURVIVING CORPORATION 2 1.1 The Merger 2 1.2 Closing 2 1.3 Effective Time 2 1.4 The Certificate of Incorporation 2 1.5 The Bylaws 2 1.6 Directors of the Sur |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 15, 2022 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 15, 2022 |
Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates Exhibit 99.1 Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates LA JOLLA, California, August 15, 2022 ? Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the second quarte |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38692 EQUILLIUM, |
|
| May 25, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 12, 2022 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 12, 2022 |
Exhibit 99.1 Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates Initiated EQUATOR Phase 3 study of itolizumab in first-line aGVHD Acquired Bioniz Therapeutics, adding two first-in-class clinical-stage assets to pipeline and proprietary product discovery platform LA JOLLA, California, May 12, 2022 - Equillium, Inc. (Nasdaq: EQ), a clinical |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38692 EQUILLIUM |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 2, 2022 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The following unaudited pro forma condensed combined financial information presents the unaudited pro forma condensed combined balance sheet as of September 30, 2021 and statements of operations for the nine months ended September 30, 2021 and year ended December 31, 2020, based upon the combined historical financial statemen |
|
| May 2, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 14, 2022 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction (Commission File |
|
| May 2, 2022 |
Exhibit 99.2 Bioniz Therapeutics, Inc Interim Condensed Financial Statements For Nine Months Ended September 30, 2021 and September 30, 2020 INDEX TO THE INTERIM CONDENSED FINANCIAL STATEMENTS Page Interim Condensed Financial Statements: Condensed Balance Sheets 3 Condensed Statements of Operations and Comprehensive Income (Loss) 4 Condensed Statements of Redeemable Convertible Preferred Stock, Co |
|
| May 2, 2022 |
Exhibit 99.1 Bioniz Therapeutics, Inc Financial Statements For Years Ended December 31, 2020 and 2019 With Report of Independent Auditors INDEX TO THE AUDITED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm 3 Financial Statements: Balance Sheets 5 Statements of Operations and Comprehensive Loss 6 Statements of Convertible Preferred Stock, Common Stock, and Stockho |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 13, 2022 |
DEF 14A 1 d307419ddef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as pe |
|
| March 23, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Equillium, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value p |
|
| March 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 23, 2022 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 23, 2022 |
Exhibit 10.25 Equillium, Inc. Non-Employee Director Compensation Policy (amended and restated, effective as of March 1, 2022) Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Equillium, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee |
|
| March 23, 2022 |
Exhibit 10.29 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE OF ALL CLAIMS This Confidential Separation Agreement and General Release of All Claims (?Separation Agreement?) is made by and between Equillium, Inc. (?Company?) and Dolca Thomas (?Employee?). The Company and Employee may also be referred to in this Separation Agreement as a Party and collectively as ?the Parties.? A. WHEREAS, Em |
|
| March 23, 2022 |
Exhibit 99.1 Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates Announced positive topline data from EQUATE study of itolizumab in first-line aGVHD Initiated EQUATOR Phase 3 study of itolizumab in first-line aGVHD Presented interim safety data and reduction in proteinuria from the EQUALISE study of itolizumab in lupus patient |
|
| March 23, 2022 |
Exhibit 10.28 CONSENT AND THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS CONSENT AND THIRD AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of February 14, 2022, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (?Oxford?), as collateral agent (in such capacity |
|
| March 23, 2022 |
Exhibit 10.23 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of December 18, 2020 (the ?Amendment Date?), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in such capacity, ?Col |
|
| March 23, 2022 |
As filed with the Securities and Exchange Commission on March 23, 2022 As filed with the Securities and Exchange Commission on March 23, 2022 Registration No. |
|
| March 23, 2022 |
Subsidiaries of Equillium, Inc. Exhibit 21.1 SUBSIDIARIES OF EQUILLIUM, INC. Name of Subsidiary Jurisdiction of Incorporation Equillium AUS Pty Ltd. Australia Bioniz Therapeutics, Inc. Delaware |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38692 EQUILLIUM, INC. |
|
| March 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 4, 2022 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 4, 2022 |
Exhibit 99.1 Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease Pivotal study to enroll up to 200 patients Global study with sites expected in North America, Europe, Asia and Australia Primary endpoint assessment of Complete Response at Day 29 LA JOLLA, California, March 4, 2022 - Equillium, Inc. (Nasdaq: EQ), a clinical-stage bi |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 24, 2022 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File |
|
| March 2, 2022 |
Equillium Announces Appointment of Barbara Troupin to Board of Directors Exhibit 99.1 Equillium Announces Appointment of Barbara Troupin to Board of Directors LA JOLLA, California, March 1, 2022 - Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the appointment of Barbara Troupin, M.D., to the Equillium Board o |
|
| February 16, 2022 |
Exhibit 2.1 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETED ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED AGREEMENT AND PLAN OF MERGER by and among Equillium, Inc.; Project JetFuel Merger Sub, Inc.; Bioniz Therapeutics, Inc. and Kevin Green, as the Securityholders? Represen |
|
| February 16, 2022 |
Equillium Acquisition of Bioniz Therapeutics 16 February 2022 Exhibit 99.2 This presentation contains forward-looking statements about Equillium, Inc. (the ?Company?). In some cases, you can identify forward-looking statements by the words ?will,? ?expect,? ?intend,? ?plan,? ?objective,? ?believe,? ?estimate,? ?potential,? ?continue? and ?ongoing,? or the negative of these terms, or other comparab |
|
| February 16, 2022 |
Exhibit 99.1 Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates Acquisition includes two first-in-class clinical-stage assets and proprietary product discovery platform Creates a robust immunology pipeline with significant value-creating milestones, and provides a strong clinical and research team with complementary expertise in immuno |
|
| February 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 11, 2022 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 14, 2022 |
EQ / Embarq Corp / Decheng Capital Management III (Cayman), LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Equillium Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 29446K106 (CUSIP Number) Laura Tse 3000 Sand Hill Road, Building 2, Suite 110 Menlo Park, CA 94025, USA 650-233-0688 (Name, Address and Telephone Number of Pers |
|
| February 1, 2022 |
EQ / Embarq Corp / VICTORY CAPITAL MANAGEMENT INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. 3)* Equillium, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29446K106 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38692 EQUIL |
|
| November 10, 2021 |
Exhibit 99.1 Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates Announced plans to initiate a pivotal study of itolizumab in first-line treatment of acute graft-versus-host disease Reported decrease in proteinuria observed in subgroup of patients with lupus following two doses of itolizumab Reported interim safety data from first cohort of asthma patie |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38692 EQUILLIUM, |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 10, 2021 |
Exhibit 99.1 Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update Announced positive topline results from the EQUATE study of itolizumab in first-line treatment of acute graft-versus-host disease Announced plans to initiate a Phase 3 pivotal study of itolizumab in first-line treatment of acute graft-versus-host disease LA JOLLA, California, August 10, 20 |
|
| July 12, 2021 |
Exhibit 99.1 Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA Single pivotal Phase 3 study in acute graft-versus-host disease to support filing of biologics license application On track to initiate study in Q4 2021 LA JOLLA, California, July 12, 2021 - Equillium, Inc. ( |
|
| July 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2021 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 14, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 09, 2021 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 11, 2021 |
Exhibit 99.1 Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease Itolizumab continues to demonstrate favorable safety and efficacy profile Rapid and durable responses resulted in clinically meaningful reduction in corticosteroid use Data support clinical advancement of itolizumab in first-line treatment of aGVHD Conference c |
|
| June 11, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 10, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 10, 2021 |
EX-99.1 2 eq-20210610ex991.htm EX-99.1 Exhibit 99.1 Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry Whole blood and proteomic stabilized blood assay used to elicit clinical pharmacodynamic CD6 biomarker in autoimmune diseases LA JOLLA, California, June 10, 2021 – Equillium, Inc. (Nasdaq: EQ), a |
|
| June 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 07, 2021 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 7, 2021 |
Exhibit 99.1 Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic Diseases LA JOLLA, California, June 7, 2021 ? Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced a translational resea |
|
| May 28, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2021 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 13, 2021 |
Exhibit 10.3 FOURTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT THIS FOURTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT ("Amendment") is made and entered into effective as of April 14, 2021 (the "Amendment Date"), by and between EQUILLIUM, INC., a corporation organized under the laws of the State of Delaware, USA, with its principal office at 2223 Avenida de la Playa, Suite 108, La Jolla |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38692 EQUILLIUM |
|
| May 13, 2021 |
Exhibit 10.4 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of April 23, 2021 (the ?Amendment Date?), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (?Oxford?), as collateral agent (in such capacity, ?Co |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Equillium, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38692 82-1554746 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 13, 2021 |
Exhibit 99.1 Equillium Reports First Quarter 2021 Financial Results and Provides Clinical Development Update Announced favorable data from Phase 1b EQUALISE study in patients with systemic lupus erythematosus Cash runway into the second half of 2023 Multiple data and regulatory catalysts through the remainder of 2021 LA JOLLA, California, May 13, 2021 - Equillium, Inc. (Nasdaq: EQ), a clinical-sta |
|
| April 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 30, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 30, 2021 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 30, 2021 |
Exhibit 99.1 Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients Itolizumab administered subcutaneously was safe and well tolerated in patients with systemic lupus erythematosus Dose-dependent changes in pharmacodynamic markers observed with subcutaneous dosing were consistent with intravenous dosing of itolizumab LA JOLLA, California, March 30, |
|
| March 24, 2021 |
Exhibit 99.1 Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update Cash runway into the second half of 2023 Announced positive interim data from EQUATE study in aGVHD Multiple data and regulatory catalysts in 2021 LA JOLLA, California, March 24, 2021 - Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab |
|
| March 24, 2021 |
As filed with the Securities and Exchange Commission on March 24, 2021 Registration No. |
|
| March 24, 2021 |
Exhibit 10.28 Equillium, Inc. Original Offer Letter Date: August 31, 2018 First Amendment to Offer Letter Effective: January 1, 2020 Amended and Restated Effective: January 26, 2021 Joel Rothman PO Box 326 Moss Beach, CA 94038 Re:Amended and Restated Employment Terms Dear Joel: Equillium, Inc. (the ?Company?) is pleased to offer you the position of Chief Development Officer on the following terms. |
|
| March 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 24, 2021 Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 24, 2021 |
Equillium, Inc. Non-Employee Director Compensation Policy, as amended. Exhibit 10.29 Equillium, Inc. Non-Employee Director Compensation Policy (amended and restated, effective as of March 4, 2021) Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Equillium, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee |
|
| March 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38692 EQUILLIUM, INC. |
|
| March 15, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 15, 2021 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 15, 2021 |
Exhibit 99.1 Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation EQUATE acute graft-versus host disease (aGVHD) study observed rapid response and durability through day 85 EQUATE aGVHD study reported a clinically meaningful reduction in corticosteroid use Tra |
|
| March 9, 2021 |
Harnessing Novel Immunobiology March 2021 www.equilliumbio.com Exhibit 99.1 Safe Harbor Statement This presentation contains forward-looking statements about Equillium, Inc. (the “Company”). In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “ongoing,” or the negative of these t |
|
| March 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 9, 2021 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2021 |
EXHIBIT 99.2 Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial reduction in baseline corticosteroid use Dose-dependent reduction of CD6 expression on CD4+ and CD8+ |
|
| February 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 12, 2021 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 12, 2021 |
Exhibit 99.1 John Koreth, Alison W. Loren, Ryotaro Nakamura, Marco Mielcarek, Trent Wang, George L. Chen, Sarah Anand, Joseph A. Pidala, Edmund K. Waller, Gabrielle Meyers, Daanish Hoda, Mark Schroeder, Jeremy Pantin, Nosha Farhadfar, Cherie Ng, Lisette M. Acevedo, Maple Fung, Joel Rothman, Stephen Connelly, Krishna R. Polu, Corey Cutler Interim results from the EQUATE Study: Preliminary safety an |
|
| February 4, 2021 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made as of the 3rd day of February, 2021, by and among Equillium, Inc., a Delaware corporation (the “Company”), and the investors set forth on the signature pages hereto (the “Investors”). THE PARTIES HEREBY AGREE AS FOLLOWS: 1. Purchase and Sale of Securities. 1.1Sale and Issuance. Subject to the te |
|
| February 4, 2021 |
Equillium Announces Pricing of $30 Million Registered Direct Offering EXHIBIT 99.1 Equillium Announces Pricing of $30 Million Registered Direct Offering LA JOLLA, Calif., February 4, 2021 – Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that it has entered into a securities purchase agreement with life science institutional investment funds managed by De |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 3, 2021 Date of Report (Date of earliest event reported) Equillium, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 4, 2021 |
EXHIBIT 4.1 EQUILLIUM, INC. WARRANT TO PURCHASE COMMON STOCK Warrant No. 2021- Original Issue Date: February 5, 2021 Equillium, Inc., a Delaware corporation (the “Company”), hereby certifies that, for value received, or its permitted registered assigns (the “Holder”), is entitled to purchase from the Company up to a total of shares of common stock, $0.0001 par value per share (the “Common Stock”), |
|
| February 4, 2021 |
4,285,710 Shares of Common Stock Warrants to Purchase 1,285,713 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-234683 PROSPECTUS SUPPLEMENT (To Prospectus dated November 25, 2019) 4,285,710 Shares of Common Stock Warrants to Purchase 1,285,713 Shares of Common Stock We are offering 4,285,710 units (each a “Unit” and collectively, the “Units”), with each Unit consisting of one share of our common stock, par value $0.0001 per share |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. )* Equillium, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29446K106 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| December 21, 2020 |
Offer Letter, dated December 15, 2020, by and between Equillium, Inc. and Dolca Thomas, M.D. EX-10.1 Exhibit 10.1 Equillium, Inc. December 15, 2020 Dolca Thomas, M.D. 2207 Sweeney Lane Alameda, CA 94501 Re: Offer of Employment Dear Dolca: Equillium, Inc. (the “Company”) is pleased to offer you the position of Executive Vice President of Research & Development & Chief Medical Officer on the following terms. You will report to the Chief Executive Officer (“CEO”), Bruce Steel. Your main offi |
|
| December 21, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 15, 2020 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission F |
|
| December 21, 2020 |
EX-99.1 Exhibit 99.1 Equillium Appoints Industry Veteran, Dolca Thomas, M.D. as Executive Vice President of Research & Development and Chief Medical Officer Equillium Further Strengthens Management Team with Additional Executive Hires LA JOLLA, Calif., Dec. 21, 2020 – Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammato |
|
| December 7, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 7, 2020 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 7, 2020 |
EX-99.1 Exhibit 99.1 Equillium Presents Translational Data Demonstrating Impact of Itolizumab on Effector T Cell Function at the 2020 American Society of Hematology Annual Meeting and Exposition Studies further support itolizumab’s potential as treatment for aGVHD patients LA JOLLA, Calif., Dec. 7, 2020 – Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to |
|
| December 4, 2020 |
EX-99.1 Virtual Investor / Analyst Day December 4, 2020 www.equilliumbio.com Exhibit 99.1 Safe Harbor Statement This presentation contains forward-looking statements about Equillium, Inc. (the “Company”). In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue”, “target”, “predict”, and “ |
|
| December 4, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 4, 2020 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 30, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 30, 2020 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission F |
|
| November 30, 2020 |
EX-99.1 Exhibit 99.1 Equillium to Host Virtual Investor and Analyst Day on December 4, 2020 Review positive interim data from the study of itolizumab for the treatment of acute GVHD and pipeline programs in lupus / lupus nephritis and uncontrolled asthma Featured guest speaker: John Koreth, M.D., D.Phil. of Dana-Farber Cancer Institute LA JOLLA, Calif, November 30, 2020 — Equillium, Inc. (Nasdaq: |
|
| November 25, 2020 |
Equillium Provides Itolizumab COVID-19 Program Update Analyst Day scheduled for December 4, 2020 EX-99.1 Exhibit 99.1 Equillium Provides Itolizumab COVID-19 Program Update Analyst Day scheduled for December 4, 2020 LA JOLLA, Calif., Nov 25, 2020 - Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that due to the rapidly evolving COVID-19 treatment landscape, the company will not ini |
|
| November 25, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 25, 2020 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission F |
|
| November 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 10, 2020 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission F |
|
| November 10, 2020 |
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights EX-99.1 Exhibit 99.1 Equillium Reports Third Quarter 2020 Financial Results and Business Highlights LA JOLLA, Calif., Nov 10, 2020 — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2020. “We continue to make significant progress towards our goal |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38692 EQUIL |
|
| October 29, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 29, 2020 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commissi |
|
| October 29, 2020 |
EX-99.1 Exhibit 99.1 Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial Equillium plans to initiate global Phase 3 COVID-19 trial – EQUINOX – during Q4 2020 FDA indicates study could support BLA filing LA JOLLA, Calif., Oct. 29, 2020 – Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, to |
|
| September 28, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 22, 2020 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) Delaware 001-38692 82-1554746 (State or other jurisdiction of incorporation) (Commission |
